American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 248-256 , August 2007

Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide

  • Amanda J. Branten, MD, PhD

      Affiliations

    • Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • A.B. and P.B.-V. contributed equally to this study.
    • ,
  • Peggy W. du Buf-Vereijken, MD, PhD

      Affiliations

    • Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands
    • A.B. and P.B.-V. contributed equally to this study.
    • ,
  • Marc Vervloet, MD

      Affiliations

    • Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.
    • ,
  • Jack F. Wetzels, MD, PhD

      Affiliations

    • Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Corresponding Author InformationAddress correspondence to Jack F. Wetzels, MD, PhD, Department of Nephrology, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.

Received 14 January 2007 ,Accepted 24 May 2007.

References 

  1. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997;30:621–631
  2. du Buf-Vereijken PWG, Branten AJW, Wetzels JFM. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46:1012–1029
  3. Branten AJW, Reichert LJM, Koene RAP, Wetzels JFM. Oral cyclophosphamide versus chlorambucil in the treatment of patients with idiopathic membranous nephropathy and renal insufficiency. QJM. 1998;91:359–366
  4. Branten AJW, Wetzels JFM. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Clin Nephrol. 2001;56:1–8
  5. du Buf-Vereijken PWG, Feith GW, Hollander D, et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: High renal survival in a large patient cohort. QJM. 2004;97:353–360
  6. du Buf-Vereijken PWG, Branten AJW, Wetzels JFM Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency; Improved renal survival but high relapse rate. Nephrol Dial Transplant. 2004;19:1142–1148
  7. Jindal K, West M, Bear R, Goldstein M. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis. 1992;19:61–67
  8. Falk RJ, Hogan SL, Muller KE, Jennette JC. Glomerular Disease Collaborative Network: Treatment of progressive membranous glomerulopathy. Ann Intern Med. 1992;116:438–445
  9. Stirling CM, Simpson K, Boulton-Jones JM. Immunosuppression and outcome in idiopathic membranous nephropathy. QJM. 1998;9:159–164
  10. Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61:219–227
  11. Cattran DC. Cytotoxics, cyclosporine and membranous nephropathy. Curr Opin Nephrol Hypertens. 1996;5:427–436
  12. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R. Long-term survival in idiopathic membranous glomerulonephritis: Can the course be clinically predicted?. Clin Nephrol. 1994;41:127–134
  13. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol. 1984;22:61–67
  14. Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998;31:1–11
  15. Mathew TH Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantion: Results at three years. Transplantation. 1998;65:1450–1454
  16. Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156–1162
  17. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation. 2005;80(suppl 2):S265–S271
  18. Wetzels JFM. Cyclophosphamide-induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis?. Neth J Med. 2004;62:347–352
  19. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477–484
  20. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: Risk and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307–1311
  21. Briggs WA, Choi MJ, Scheel PJ. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998;31:213–217
  22. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002;61:1098–1114
  23. Miller G, Zimmerman R, Radhakrishnan J, Appel GB. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis. 2000;36:250–256
  24. Polenakovic M. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant. 2003;18:1233–1234
  25. Ponticelli C, Zucchelli P, Passerini P, Cesana B Italian Idiopathic Membranous Nephropathy Treatment Study Group. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med. 1992;327:599–603
  26. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444–450

 Originally published online as doi:10.1053/j.ajkd.2007.05.015 on June 28, 2007.

 Trial registration:www.clinicaltrials.gov; study number: NCT00135967.

PII: S0272-6386(07)00841-4

doi: 10.1053/j.ajkd.2007.05.015

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 248-256 , August 2007

Article Tools

* Image Usage & Resolution